The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity
The aim of the present study was to clarify whether gastric antisecretory drugs affect the clinical efficacy and toxicity of orally administered melphalan in patients with multiple myeloma. A total of 10 patients receiving bortezomib plus oral melphalan and prednisolone (VMP) therapy between Decembe...
Gespeichert in:
| Veröffentlicht in: | Molecular and clinical oncology 2016-02, Vol.4 (2), p.293-297 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 297 |
|---|---|
| container_issue | 2 |
| container_start_page | 293 |
| container_title | Molecular and clinical oncology |
| container_volume | 4 |
| creator | KITAZAWA, FUMIAKI KADO, YOKO UEDA, KUMI KOKUFU, TAKATOSHI FUCHIDA, SHIN-ICHI OKANO, AKIRA HATSUSE, MAYUMI MURAKAMI, SATOSHI NAKAYAMA, YUKO TAKARA, KOHJI SHIMAZAKI, CHIHIRO |
| description | The aim of the present study was to clarify whether gastric antisecretory drugs affect the clinical efficacy and toxicity of orally administered melphalan in patients with multiple myeloma. A total of 10 patients receiving bortezomib plus oral melphalan and prednisolone (VMP) therapy between December 2011 and November 2014 were analyzed retrospectively. The patients were divided into a control group (seven patients) and a concomitant group (three patients, who were also administered with gastric antisecretory drugs). The gastric antisecretory drugs included rabeprazole sodium (two patients) and famotidine (one patient). No significant differences between the groups were observed in either the characteristics of the patients or the VMP regimen. The levels of monoclonal protein (M protein) in the control group tended to decrease (with a VMP cycle-dependency), although they were primarily stable in the concomitant group. During the second and third VMP cycles, the levels of M protein were markedly lower in the control group compared with the concomitant group. All the patients in the control group achieved a partial response, whereas those in the concomitant group exhibited stable disease. Hematological toxicity levels were revealed to be comparable between the two groups, whereas gastrointestinal toxicity was more prevalent in the control group. In conclusion, the results of the present study suggested that the clinical efficacy of melphalan may be reduced by the co-administration of gastric antisecretory drugs. This interaction may result in decreased toxicity and clinical efficacy of melphalan. |
| doi_str_mv | 10.3892/mco.2015.683 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4733945</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A444309533</galeid><sourcerecordid>A444309533</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-d10f3718d127104d643e2a4bb9e68abdff0b5d6649f66934d727dec78d5cdbd33</originalsourceid><addsrcrecordid>eNptks9vFCEUxydGY5vam2cziR48uCsDDAMemjQbfzSp6aWeCQNvdmlmYARW3f_et25drREOvMDnfeE9vlX1vCFLJhV9O9m4pKRpl0KyR9UpJVwtFBfq8TFuyUl1nvMdwaE6Qlv1tDqhQiomO3lazbcbqH0okIwtPoa6h_IdINQxmbGeYJw3ZjShNsHVa5NL8hbj4jPYBCWmXe3Sdp3f1VfTjAo1KtjRB28xG4YBV7v7lVziD2992T2rngxmzHB-v55VXz68v119WlzffLxaXV4vLGeyLFxDBtY10jW0awh3gjOghve9AiFN74aB9K0TgqtBCMW462jnwHbStdb1jrGz6uKgO2_7CZyFULAiPSc_mbTT0Xj98CT4jV7Hb5p3jGHbUOD1vUCKX7eQi558tjBiNyBus24kFaIVVFJEX_6D3sVtCliebhSjvG0k6f5QazOC9mGIeK_di-pLzjkjqmX7dy__Q-F0MHkbAwwe9x8kvDkk2BRzTjAca2yI3ptEo0n03iQaTYL4i7_7coR_WwKBVwcgz_hv3sV8ZD6vbhYE517nJ6MTxKg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932451807</pqid></control><display><type>article</type><title>The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>KITAZAWA, FUMIAKI ; KADO, YOKO ; UEDA, KUMI ; KOKUFU, TAKATOSHI ; FUCHIDA, SHIN-ICHI ; OKANO, AKIRA ; HATSUSE, MAYUMI ; MURAKAMI, SATOSHI ; NAKAYAMA, YUKO ; TAKARA, KOHJI ; SHIMAZAKI, CHIHIRO</creator><creatorcontrib>KITAZAWA, FUMIAKI ; KADO, YOKO ; UEDA, KUMI ; KOKUFU, TAKATOSHI ; FUCHIDA, SHIN-ICHI ; OKANO, AKIRA ; HATSUSE, MAYUMI ; MURAKAMI, SATOSHI ; NAKAYAMA, YUKO ; TAKARA, KOHJI ; SHIMAZAKI, CHIHIRO</creatorcontrib><description>The aim of the present study was to clarify whether gastric antisecretory drugs affect the clinical efficacy and toxicity of orally administered melphalan in patients with multiple myeloma. A total of 10 patients receiving bortezomib plus oral melphalan and prednisolone (VMP) therapy between December 2011 and November 2014 were analyzed retrospectively. The patients were divided into a control group (seven patients) and a concomitant group (three patients, who were also administered with gastric antisecretory drugs). The gastric antisecretory drugs included rabeprazole sodium (two patients) and famotidine (one patient). No significant differences between the groups were observed in either the characteristics of the patients or the VMP regimen. The levels of monoclonal protein (M protein) in the control group tended to decrease (with a VMP cycle-dependency), although they were primarily stable in the concomitant group. During the second and third VMP cycles, the levels of M protein were markedly lower in the control group compared with the concomitant group. All the patients in the control group achieved a partial response, whereas those in the concomitant group exhibited stable disease. Hematological toxicity levels were revealed to be comparable between the two groups, whereas gastrointestinal toxicity was more prevalent in the control group. In conclusion, the results of the present study suggested that the clinical efficacy of melphalan may be reduced by the co-administration of gastric antisecretory drugs. This interaction may result in decreased toxicity and clinical efficacy of melphalan.</description><identifier>ISSN: 2049-9450</identifier><identifier>EISSN: 2049-9469</identifier><identifier>DOI: 10.3892/mco.2015.683</identifier><identifier>PMID: 26893878</identifier><language>eng</language><publisher>England: D.A. Spandidos</publisher><subject>Analysis ; Anemia ; Bioavailability ; Care and treatment ; Community health care ; Dosage and administration ; Drug dosages ; drug interaction ; Drug therapy ; famotidine ; Hematology ; Melphalan ; Multiple myeloma ; Oncology ; Patients ; Proteins ; rabeprazole sodium ; Studies ; VMP ; Working groups</subject><ispartof>Molecular and clinical oncology, 2016-02, Vol.4 (2), p.293-297</ispartof><rights>Copyright © 2016, Spandidos Publications</rights><rights>COPYRIGHT 2016 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2016</rights><rights>Copyright © 2016, Spandidos Publications 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-d10f3718d127104d643e2a4bb9e68abdff0b5d6649f66934d727dec78d5cdbd33</citedby><cites>FETCH-LOGICAL-c438t-d10f3718d127104d643e2a4bb9e68abdff0b5d6649f66934d727dec78d5cdbd33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733945/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733945/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,5571,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26893878$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KITAZAWA, FUMIAKI</creatorcontrib><creatorcontrib>KADO, YOKO</creatorcontrib><creatorcontrib>UEDA, KUMI</creatorcontrib><creatorcontrib>KOKUFU, TAKATOSHI</creatorcontrib><creatorcontrib>FUCHIDA, SHIN-ICHI</creatorcontrib><creatorcontrib>OKANO, AKIRA</creatorcontrib><creatorcontrib>HATSUSE, MAYUMI</creatorcontrib><creatorcontrib>MURAKAMI, SATOSHI</creatorcontrib><creatorcontrib>NAKAYAMA, YUKO</creatorcontrib><creatorcontrib>TAKARA, KOHJI</creatorcontrib><creatorcontrib>SHIMAZAKI, CHIHIRO</creatorcontrib><title>The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity</title><title>Molecular and clinical oncology</title><addtitle>Mol Clin Oncol</addtitle><description>The aim of the present study was to clarify whether gastric antisecretory drugs affect the clinical efficacy and toxicity of orally administered melphalan in patients with multiple myeloma. A total of 10 patients receiving bortezomib plus oral melphalan and prednisolone (VMP) therapy between December 2011 and November 2014 were analyzed retrospectively. The patients were divided into a control group (seven patients) and a concomitant group (three patients, who were also administered with gastric antisecretory drugs). The gastric antisecretory drugs included rabeprazole sodium (two patients) and famotidine (one patient). No significant differences between the groups were observed in either the characteristics of the patients or the VMP regimen. The levels of monoclonal protein (M protein) in the control group tended to decrease (with a VMP cycle-dependency), although they were primarily stable in the concomitant group. During the second and third VMP cycles, the levels of M protein were markedly lower in the control group compared with the concomitant group. All the patients in the control group achieved a partial response, whereas those in the concomitant group exhibited stable disease. Hematological toxicity levels were revealed to be comparable between the two groups, whereas gastrointestinal toxicity was more prevalent in the control group. In conclusion, the results of the present study suggested that the clinical efficacy of melphalan may be reduced by the co-administration of gastric antisecretory drugs. This interaction may result in decreased toxicity and clinical efficacy of melphalan.</description><subject>Analysis</subject><subject>Anemia</subject><subject>Bioavailability</subject><subject>Care and treatment</subject><subject>Community health care</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>drug interaction</subject><subject>Drug therapy</subject><subject>famotidine</subject><subject>Hematology</subject><subject>Melphalan</subject><subject>Multiple myeloma</subject><subject>Oncology</subject><subject>Patients</subject><subject>Proteins</subject><subject>rabeprazole sodium</subject><subject>Studies</subject><subject>VMP</subject><subject>Working groups</subject><issn>2049-9450</issn><issn>2049-9469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptks9vFCEUxydGY5vam2cziR48uCsDDAMemjQbfzSp6aWeCQNvdmlmYARW3f_et25drREOvMDnfeE9vlX1vCFLJhV9O9m4pKRpl0KyR9UpJVwtFBfq8TFuyUl1nvMdwaE6Qlv1tDqhQiomO3lazbcbqH0okIwtPoa6h_IdINQxmbGeYJw3ZjShNsHVa5NL8hbj4jPYBCWmXe3Sdp3f1VfTjAo1KtjRB28xG4YBV7v7lVziD2992T2rngxmzHB-v55VXz68v119WlzffLxaXV4vLGeyLFxDBtY10jW0awh3gjOghve9AiFN74aB9K0TgqtBCMW462jnwHbStdb1jrGz6uKgO2_7CZyFULAiPSc_mbTT0Xj98CT4jV7Hb5p3jGHbUOD1vUCKX7eQi558tjBiNyBus24kFaIVVFJEX_6D3sVtCliebhSjvG0k6f5QazOC9mGIeK_di-pLzjkjqmX7dy__Q-F0MHkbAwwe9x8kvDkk2BRzTjAca2yI3ptEo0n03iQaTYL4i7_7coR_WwKBVwcgz_hv3sV8ZD6vbhYE517nJ6MTxKg</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>KITAZAWA, FUMIAKI</creator><creator>KADO, YOKO</creator><creator>UEDA, KUMI</creator><creator>KOKUFU, TAKATOSHI</creator><creator>FUCHIDA, SHIN-ICHI</creator><creator>OKANO, AKIRA</creator><creator>HATSUSE, MAYUMI</creator><creator>MURAKAMI, SATOSHI</creator><creator>NAKAYAMA, YUKO</creator><creator>TAKARA, KOHJI</creator><creator>SHIMAZAKI, CHIHIRO</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160201</creationdate><title>The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity</title><author>KITAZAWA, FUMIAKI ; KADO, YOKO ; UEDA, KUMI ; KOKUFU, TAKATOSHI ; FUCHIDA, SHIN-ICHI ; OKANO, AKIRA ; HATSUSE, MAYUMI ; MURAKAMI, SATOSHI ; NAKAYAMA, YUKO ; TAKARA, KOHJI ; SHIMAZAKI, CHIHIRO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-d10f3718d127104d643e2a4bb9e68abdff0b5d6649f66934d727dec78d5cdbd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>Anemia</topic><topic>Bioavailability</topic><topic>Care and treatment</topic><topic>Community health care</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>drug interaction</topic><topic>Drug therapy</topic><topic>famotidine</topic><topic>Hematology</topic><topic>Melphalan</topic><topic>Multiple myeloma</topic><topic>Oncology</topic><topic>Patients</topic><topic>Proteins</topic><topic>rabeprazole sodium</topic><topic>Studies</topic><topic>VMP</topic><topic>Working groups</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KITAZAWA, FUMIAKI</creatorcontrib><creatorcontrib>KADO, YOKO</creatorcontrib><creatorcontrib>UEDA, KUMI</creatorcontrib><creatorcontrib>KOKUFU, TAKATOSHI</creatorcontrib><creatorcontrib>FUCHIDA, SHIN-ICHI</creatorcontrib><creatorcontrib>OKANO, AKIRA</creatorcontrib><creatorcontrib>HATSUSE, MAYUMI</creatorcontrib><creatorcontrib>MURAKAMI, SATOSHI</creatorcontrib><creatorcontrib>NAKAYAMA, YUKO</creatorcontrib><creatorcontrib>TAKARA, KOHJI</creatorcontrib><creatorcontrib>SHIMAZAKI, CHIHIRO</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KITAZAWA, FUMIAKI</au><au>KADO, YOKO</au><au>UEDA, KUMI</au><au>KOKUFU, TAKATOSHI</au><au>FUCHIDA, SHIN-ICHI</au><au>OKANO, AKIRA</au><au>HATSUSE, MAYUMI</au><au>MURAKAMI, SATOSHI</au><au>NAKAYAMA, YUKO</au><au>TAKARA, KOHJI</au><au>SHIMAZAKI, CHIHIRO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity</atitle><jtitle>Molecular and clinical oncology</jtitle><addtitle>Mol Clin Oncol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>4</volume><issue>2</issue><spage>293</spage><epage>297</epage><pages>293-297</pages><issn>2049-9450</issn><eissn>2049-9469</eissn><abstract>The aim of the present study was to clarify whether gastric antisecretory drugs affect the clinical efficacy and toxicity of orally administered melphalan in patients with multiple myeloma. A total of 10 patients receiving bortezomib plus oral melphalan and prednisolone (VMP) therapy between December 2011 and November 2014 were analyzed retrospectively. The patients were divided into a control group (seven patients) and a concomitant group (three patients, who were also administered with gastric antisecretory drugs). The gastric antisecretory drugs included rabeprazole sodium (two patients) and famotidine (one patient). No significant differences between the groups were observed in either the characteristics of the patients or the VMP regimen. The levels of monoclonal protein (M protein) in the control group tended to decrease (with a VMP cycle-dependency), although they were primarily stable in the concomitant group. During the second and third VMP cycles, the levels of M protein were markedly lower in the control group compared with the concomitant group. All the patients in the control group achieved a partial response, whereas those in the concomitant group exhibited stable disease. Hematological toxicity levels were revealed to be comparable between the two groups, whereas gastrointestinal toxicity was more prevalent in the control group. In conclusion, the results of the present study suggested that the clinical efficacy of melphalan may be reduced by the co-administration of gastric antisecretory drugs. This interaction may result in decreased toxicity and clinical efficacy of melphalan.</abstract><cop>England</cop><pub>D.A. Spandidos</pub><pmid>26893878</pmid><doi>10.3892/mco.2015.683</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2049-9450 |
| ispartof | Molecular and clinical oncology, 2016-02, Vol.4 (2), p.293-297 |
| issn | 2049-9450 2049-9469 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4733945 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Analysis Anemia Bioavailability Care and treatment Community health care Dosage and administration Drug dosages drug interaction Drug therapy famotidine Hematology Melphalan Multiple myeloma Oncology Patients Proteins rabeprazole sodium Studies VMP Working groups |
| title | The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T01%3A45%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20interaction%20between%20oral%20melphalan%20and%20gastric%20antisecretory%20drugs:%20Impact%20on%20clinical%20efficacy%20and%20toxicity&rft.jtitle=Molecular%20and%20clinical%20oncology&rft.au=KITAZAWA,%20FUMIAKI&rft.date=2016-02-01&rft.volume=4&rft.issue=2&rft.spage=293&rft.epage=297&rft.pages=293-297&rft.issn=2049-9450&rft.eissn=2049-9469&rft_id=info:doi/10.3892/mco.2015.683&rft_dat=%3Cgale_pubme%3EA444309533%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932451807&rft_id=info:pmid/26893878&rft_galeid=A444309533&rfr_iscdi=true |